Known targets — ChEMBL curated mechanism
TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8
The experimentally established mechanism targets of Indibulin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A known ✓ | P04350 | 1/20 | 1.00 |
| ▸ | TUBB known ✓ | P07437 | 1/20 | 1.00 |
| ▸ | TUBA3C known ✓ | P0DPH7 | 1/20 | 1.00 |
| ▸ | TUBA1B known ✓ | P68363 | 1/20 | 1.00 |
| ▸ | TUBA4A known ✓ | P68366 | 1/20 | 1.00 |
| ▸ | TUBB4B known ✓ | P68371 | 1/20 | 1.00 |
| ▸ | TUBB3 known ✓ | Q13509 | 1/20 | 1.00 |
| ▸ | TUBB2A known ✓ | Q13885 | 1/20 | 1.00 |
| ▸ | TUBB8 known ✓ | Q3ZCM7 | 1/20 | 1.00 |
| ▸ | TUBA3E known ✓ | Q6PEY2 | 1/20 | 1.00 |
| ▸ | TUBA1A known ✓ | Q71U36 | 1/20 | 1.00 |
| ▸ | TUBA1C known ✓ | Q9BQE3 | 1/20 | 1.00 |
| ▸ | TUBB6 known ✓ | Q9BUF5 | 1/20 | 1.00 |
| ▸ | TUBB2B known ✓ | Q9BVA1 | 1/20 | 1.00 |
| ▸ | TUBB1 known ✓ | Q9H4B7 | 1/20 | 1.00 |
| ▸ | YES1 | P07947 | 1/20 | 0.65 |
| ▸ | KDR | P35968 | 1/20 | 0.65 |
| ▸ | JAK3 | P52333 | 1/20 | 0.65 |
| ▸ | CNR2 | P34972 | 2/20 | 0.53 |
| ▸ | CNR1 | P21554 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Indibulin SCHEMBL3165856 | 1.00 | TUBB4A (1.00) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL3166384 | 0.92 | TUBB4A (0.85) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL23625291 | 0.90 | TUBB4A (0.82) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL15908288 | 0.90 | TUBB4A (0.82) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL3151543 | 0.90 | TUBB4A (0.82) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL6103193 | 0.90 | TUBB4A (0.82) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL23625153 | 0.90 | TUBB4A (0.81) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Hydrochloric Acid SCHEMBL4920187 | 0.89 | TUBB4A (0.81) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL6581881 | 0.87 | TUBB4A (0.76) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL3847245 | 0.86 | TUBB4A (0.76) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 929 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12626784-B2 | Colorectal cancer consensus molecular subtype classifier codesets and methods of use thereof | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2026-05-12 | — | — | US | claimed |
| EP-4674894-A2 | COPOLYMERS OF N-VINYLPYRROLIDONE WITH FUNCTIONALIZED MALEIC ACID MOIETIES | Hemoteq AG (DE) | 2026-01-07 | — | — | EP | claimed |
| EP-4663688-A2 | CROSSLINKERS | Hemoteq AG (DE) | 2025-12-17 | — | — | EP | claimed |
| EP-4642492-A1 | AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE FUNCTIONAL SMALL MOLECULE COMPOUNDS FOR ENHANCED TREATMENT OF REFRACTORY DISEASES | Hangzhou Seehe Biotechnology Co., Ltd (CN) | 2025-11-05 | — | — | EP | claimed |
| EP-4642484-A1 | TARGETED TREATMENT OF PROSTATE CANCERS AND OTHER TUMORS BY AN ANTIBODY-DRUG CONJUGATE | Hangzhou Seehe Biotechnology Co., Ltd (CN) | 2025-11-05 | — | — | EP | claimed |
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| EP-4479042-A1 | CANCER TREATMENT BY COMBINED INHIBITION OF POLO-LIKE KINASE AND MICROTUBULE POLYMERIZATION | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2024-12-25 | — | — | EP | claimed |
| WO-2024239281-A1 | TARGETED TREATMENT OF PROSTATE CANCERS AND OTHER TUMORS BY AN ANTIBODY-DRUG CONJUGATE | HANGZHOU SEEHE BIOTECHNOLOGY CO., LTD (CN) | 2024-11-28 | — | — | WO | claimed |
| WO-2024240173-A1 | AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE FUNCTIONAL SMALL MOLECULE COMPOUNDS FOR ENHANCED TREATMENT OF REFRACTORY DISEASES | HANGZHOU SEEHE BIOTECHNOLOGY CO., LTD (CN) | 2024-11-28 | — | — | WO | claimed |
| US-12102653-B2 | Ligand regulated protein-protein interaction system | ST. ANNA KINDERKREBSFORSCHUNG (AT) | 2024-10-01 | — | — | US | claimed |
| US-20230115871-A1 | A CONJUGATE OF A CYTOTOXIC AGENT TO A CELL BINDING MOLECULE WITH BRANCHED LINKERS | HANGZHOU DAC BIOTECH CO., LTD (CN) | 2023-04-13 | — | — | US | claimed |
| US-20230057350-A1 | A CONJUGATE OF AN AMANITA TOXIN WITH BRANCHED LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2023-02-23 | — | — | US | claimed |
| US-20230010108-A1 | A CONJUGATION LINKER CONTAINING 2,3-DIAMINOSUCCINYL GROUP | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2023-01-12 | — | — | US | claimed |
| WO-2022078524-A4 | SPECIFIC CONJUGATION OF AN ANTIBODY | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2022-12-08 | — | — | WO | claimed |
| US-20220362381-A1 | REMOTELY TRIGGERED THERAPY | BAMBU VAULT LLC (US) | 2022-11-17 | — | — | US | claimed |
| WO-2022162665-A1 | SETDB1-MICROTUBULE INTERACTION AND USE THEREOF | Ariel Scientific Innovations Ltd. (IL) | 2022-08-04 | — | — | WO | claimed |
| US-20220180974-A1 | COLORECTAL CANCER CONSENSUS MOLECULAR SUBTYPE CLASSIFIER CODESETS AND METHODS OF USE THEREOF | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-06-09 | — | — | US | claimed |
| EP-3986463-A1 | A CONJUGATE OF A CYTOTOXIC AGENT TO A CELL BINDING MOLECULE WITH BRANCHED LINKERS | Hangzhou Dac Biotech Co., Ltd. (CN) | 2022-04-27 | — | — | EP | claimed |
| WO-2022078524-A2 | SPECIFIC CONJUGATION OF AN ANTIBODY | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2022-04-21 | — | — | WO | claimed |
| WO-2022056021-A1 | METHODS OF DETECTING AN INACTIVATING MUTATION OF PBRM1 IN MENINGIOMA | FOUNDATION MEDICINE, INC. (US) | 2022-03-17 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230057350-A1 | A CONJUGATE OF AN AMANITA TOXIN WITH BRANCHED LINKERS | BTN3A1, ANTXR2, CLTA | TUBB4A 166/4885TUBB 61/4885TUBA3C 117/4885 |
| US-20220362381-A1 | REMOTELY TRIGGERED THERAPY | CD47, HSP90AA1, HSF1 | TUBB4A 502/4885TUBB 558/4885TUBA3C 1142/4885 |
| US-20230010108-A1 | A CONJUGATION LINKER CONTAINING 2,3-DIAMINOSUCCINYL GROUP | DAO, DDO, DCLRE1A | TUBB4A 278/4885TUBB 125/4885TUBA3C 284/4885 |
| US-20230115871-A1 | A CONJUGATE OF A CYTOTOXIC AGENT TO A CELL BINDING MOLECULE WITH BRANCHED LINKERS | CD2BP2, EPCAM, CD74 | TUBB4A 238/4885TUBB 128/4885TUBA3C 323/4885 |
| US-12626784-B2 | Colorectal cancer consensus molecular subtype classifier codesets and methods of use thereof | CYTH3, DCLRE1B, DDX24 | TUBB4A 535/4885TUBB 1607/4885TUBA3C 2716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.